RiTUXimab-hyaluronidase
Restricted to oncology use in outpatient setting (clinic, outpatient medical). Not routinely stocked.
Patient should be observed/monitored for at least 15 minutes post-dose for signs of hypersensitivity or other adverse drug reactions.
Reviewed: 23 Jan 2018
Restricted to oncology use in outpatient setting (clinic, outpatient medical). Not routinely stocked.
Patient should be observed/monitored for at least 15 minutes post-dose for signs of hypersensitivity or other adverse drug reactions.
Reviewed: 23 Jan 2018